|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.28 USD | -0.40% |
|
-0.20% | +29.90% |
| 22/07 | Celldex Therapeutics, Inc. - Special Call | |
| 22/07 | Celldex's Phase 3 Barzolvolimab Study in Chronic Spontaneous Urticaria in Focus After Prurigo Nodularis Exit, Morgan Stanley Says | MT |
| Market Cap | 276.92Cr 243.22Cr 226.19Cr 207.56Cr 389.98Cr 27TCr 396Cr 2.69TCr 1.05TCr 13TCr 1.04TCr 1.02TCr 45TCr | P/E 2026 * |
-8.13x | P/E 2027 * | -8.13x |
|---|---|---|---|---|---|
| Enterprise Value | 218.51Cr 191.92Cr 178.48Cr 163.78Cr 307.72Cr 21TCr 312.47Cr 2.12TCr 828.02Cr 10TCr 820.28Cr 802.6Cr 36TCr | EV / Sales 2026 * |
904x | EV / Sales 2027 * | 204x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | -0.40% | ||
| 1 week | -0.20% | ||
| Current month | -5.19% | ||
| 1 month | +0.06% | ||
| 3 months | +5.98% | ||
| 6 months | +32.78% | ||
| Current year | +29.90% |
| 1 week | 33.37 |  | 36.09 |
| 1 month | 33.37 | | 40.3 |
| Current year | 22.33 | | 40.3 |
| 1 year | 19.72 | | 40.3 |
| 3 years | 14.4 | | 53.18 |
| 5 years | 14.4 | | 57.2 |
| 10 years | 1.5 | | 75.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 30/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 01/09/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 01/04/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 01/12/2008 |
Harry Penner
CHM | Chairman | 80 | 05/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 01/03/2008 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 25/06/26 | Free | Founder | 3,75,000 | 0.4778% | ||
| 25/06/26 | Free | Director | 26,000 | 0.0331% | ||
| 25/06/26 | Free | Director | 26,000 | 0.0331% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.40% | -0.20% | +51.09% | -1.62% | 276.92Cr | |
| +1.07% | -3.49% | -3.35% | +11.75% | 4.69TCr | |
| +0.25% | +1.65% | +399.22% | +647.65% | 4.02TCr | |
| -0.27% | +4.45% | +11.81% | +60.81% | 3.62TCr | |
| +0.35% | +0.87% | +4.46% | -10.31% | 3.47TCr | |
| +3.14% | +1.02% | +4.76% | +43.00% | 2.79TCr | |
| -0.73% | +11.84% | +34.39% | +134.44% | 1.68TCr | |
| +0.47% | -2.74% | - | - | 1.67TCr | |
| +0.42% | -5.52% | -3.43% | +9.10% | 1.31TCr | |
| -2.68% | -2.49% | -11.36% | -34.51% | 1.27TCr | |
| Average | +0.16% | +0.73% | +54.18% | +95.59% | 2.48TCr | |
| Weighted average by Cap. | +0.47% | +0.90% | +74.14% | +136.54% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 24.16L 21.22L 19.74L 18.11L 34.03L 23Cr 34.55L 2.34Cr 91.57L 11Cr 90.71L 88.76L 40Cr | 1.1Cr 96.98L 90.19L 82.76L 1.56Cr 106.34Cr 1.58Cr 11Cr 4.18Cr 52Cr 4.15Cr 4.06Cr 180.76Cr |
| Net income | -33Cr -29Cr -27Cr -25Cr -46Cr -3.18TCr -47Cr -320.13Cr -125.07Cr -1.56TCr -123.9Cr -121.23Cr -5.4TCr | -37Cr -32Cr -30Cr -28Cr -52Cr -3.54TCr -53Cr -356.44Cr -139.26Cr -1.74TCr -137.96Cr -134.98Cr -6.02TCr |
| Net Debt | -58Cr -51Cr -48Cr -44Cr -82Cr -5.63TCr -84Cr -566.55Cr -221.34Cr -2.77TCr -219.28Cr -214.55Cr -9.56TCr | -52Cr -45Cr -42Cr -39Cr -73Cr -4.96TCr -74Cr -499.59Cr -195.18Cr -2.44TCr -193.36Cr -189.19Cr -8.43TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/26/24 | $35.28 | -0.40% | 6,39,231 |
| 23/26/23 | $35.42 | +1.87% | 8,56,468 |
| 22/26/22 | $34.77 | -2.50% | 19,28,820 |
| 21/26/21 | $35.66 | +0.68% | 13,92,017 |
| 20/26/20 | $35.42 | +0.20% | 5,27,637 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CLDX Stock
Select your edition
All financial news and data tailored to specific country editions
